BiotechTube

FK506 + placebo

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Keratoconjunctivitis

Conditions

Keratoconjunctivitis, Conjunctivitis

Trial Timeline

Feb 1, 2004 → Sep 1, 2004

NCT ID
NCT00567762

About FK506 + placebo

FK506 + placebo is a phase 3 stage product being developed by Astellas Pharma for Keratoconjunctivitis. The current trial status is completed. This product is registered under clinical trial identifier NCT00567762. Target conditions include Keratoconjunctivitis, Conjunctivitis.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT00567762Phase 3Completed

Competing Products

15 competing products in Keratoconjunctivitis

See all competitors
ProductCompanyStageHype Score
FK506Astellas PharmaPhase 3
77
OTX-101 0.09%Sun PharmaceuticalPhase 3
77
OTX-101 0.05% + OTX-101 0.09% + VehicleSun PharmaceuticalPhase 2/3
65
cyclosporine + vehicle of OTX-101Sun PharmaceuticalPhase 3
77
INS365 Ophthalmic SolutionMerckPhase 3
77
Pimecrolimus + VehicleNovartisPhase 2
52
Cyclosporine A + DexamethasoneNovartisApproved
85
RebamipideNovartisPhase 3
77
RebamipideNovartisPhase 3
77
Tasocitinib + Tasocitinib + vehicle for TasocitinibPfizerPhase 2
51
DupilumabRegeneron PharmaceuticalsPhase 2
51
R348 Ophthalmic Solution, 0.2% + R348 Ophthalmic Solution, 0.5% + R348 Ophthalmic Solution, 1.0% + PlaceboRigel PharmaceuticalsPhase 1
25
R348 Ophthalmic Solution, 0.2% + R348 Ophthalmic Solution, 0.5% + PlaceboRigel PharmaceuticalsPhase 2
44
CF101Can Fite BiopharmaPhase 3
69
CF101 + PlaceboCan Fite BiopharmaPhase 2
44

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved
85
micafungin + voriconazoleApproved
85
mirabegron + solifenacinApproved
85
Zolpidem (Myslee®) + placeboApproved
85
TacrolimusApproved
85